Ata B, Urman B Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression? Reprod Biomed Online. 2010 Jan;20(1):165-6; author reply 167.
Ata B, Yakin K, Balaban B, Urman B GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum Reprod. 2008 Mar;23(3):668-73. doi: 10.1093/hum
Bar Hava I, Blueshtein M, Ganer Herman H, Omer Y, Ben David G Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles. Fertil Steril. 2017 Jan;107(1):130-135.e1. doi: 10.1016/j.fertnstert
Benmachiche A, Benbouhedja S, Zoghmar A, Boularak A, Humaidan P Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial. Front Endocrinol (Lausanne). 2017 Jun 15;8:12
Chen SL, Wu FR, Luo C, Chen X, Shi XY, Zheng HY, Ni YP Combined analysis of endometrial thickness and pattern in predicting outcome of in vitro fertilization and embryo transfer: a retrospective cohort study. Reprod Biol Endocrinol. 2010 Mar 24;8:30. doi
Davar R, Farid Mojtahedi M, Miraj S Effects of single dose GnRH agonist as luteal support on pregnancy outcome in frozen-thawed embryo transfer cycles: an RCT. Iran J Reprod Med. 2015 Aug;13(8):483-8.
Dupont WD, Plummer WD Jr Power and sample size calculations. A review and computer program. Control Clin Trials. 1990 Apr;11(2):116-28.
Pirard C, Donnez J, Loumaye E GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006 Jul;21(7):1894-900. Epub 2006 Mar 23.
Pirard C, Donnez J, Loumaye E GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod. 2005 Jul;20(7):1798-804. Epub 2005 May 12.
Pritts EA, Atwood AK Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002 Sep;17(9):2287-99. Review.
Tesarik J, Hazout A, Mendoza C Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004 May;19(5):1176-80. Epub 2004 Apr 7.
Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(
Ye H, Luo X, Pei L, Li F, Li C, Chen Y, Zhang X, Huang G The addition of single dose GnRH agonist to luteal phase support in artificial cycle frozen embryo transfer: a randomized clinical trial. Gynecol Endocrinol. 2019 Jul;35(7):618-622. doi: 10.1080/09
Yildiz GA, Sükür YE, Ates C, Aytaç R The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 20
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
